

---

## Collaborative Working Executive Summary

### **Project Name:**

National Optimal Lung Cancer Pathway Analysis Model (NOLCP model)

### **Project Partners:**

Roche Products Limited

East of England Cancer Alliance

Mid and South Essex NHS Foundation Trust

University Hospitals of Derby and Burton NHS Foundation Trust

### **Roche Contribution:**

Roche Products Ltd contributed £48,000 and people resources to this project.

East of England Cancer Alliance, Mid and South Essex NHS Foundation Trust and University Hospitals of Derby and Burton NHS Foundation Trust contributed people resources to this project

### **Duration:**

2021 – 2023

### **Project Overview:**

Roche Products Ltd, East of England Cancer Alliance, Mid and South Essex NHS Foundation Trust, and University Hospitals of Derby and Burton NHS Foundation Trust worked together under a Collaborative Working Agreement with the aim of helping NHS organisations to monitor performance of the National Optimal Lung Cancer Pathway (NOLCP) and identify areas for service development/improvement.

The collaboration sought to develop a model to map the NOLCP from referral to diagnosis, and for those diagnosed with lung cancer, the time to first treatment – i.e. to assess performance versus the 28- and 62-day lung cancer targets. The collaboration also sought to facilitate automated data entry into the model.

### **Project Outcomes:**

The National Optimal Lung Cancer Pathway (NOLCP) model was developed and tested in Mid and South Essex NHS Foundation Trust and University Hospitals of Derby and Burton NHS Foundation Trust under this agreement. It was then made available to other NHS Trusts through a Donation Agreement, initially supported by the East of England Cancer Alliance, and was taken up by 9 NHS Trusts by the end of 2023.

In July 2022, the NHS England Get It Right First Time (GIRFT) Joint Clinical Lead for Lung Cancer wrote to NHS Trusts and Cancer Alliances in England supporting the use of the NOLCP model in NHS Trust's and Cancer Alliance's implementation of the recommendations and

---

## Collaborative Working Executive Summary

actions from the GIRFT National Report for Lung Cancer<sup>1</sup>.

### Conclusions and Learnings:

The NOLCP continues to be available to NHS Trusts and Cancer Alliances from Roche as a Donation Agreement. It is possible that the model may be amended to be used for other tumour types. In 2024 Roche developed it into a Breast Cancer Model and also offers this to NHS Trusts and Cancer Alliances via a Donation Agreement.

### References:

1. GIRFT National Report for Lung Cancer: <https://gettingitrightfirsttime.co.uk/wp-content/uploads/2025/01/Lung-Cancer-National-Report-07-10j-FINAL.pdf>